Better Buy: AbbVie vs. Eli Lilly
Biopharmaceutical giants AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have both provided shareholders with market-crushing returns over the past five years. The secret to their success has been their laserlike focus on creating value for shareholders through various business development activities, an aggressive approach to clinical trials, and regular hikes to their respective dividend programs.
AbbVie and Lilly, in fact, have been two of the most generous pharma companies over this period in terms of raising their dividends. Keeping with this theme, AbbVie has boosted its dividend by a staggering 141% since the start of 2015, whereas Lilly has hiked its annual payout by 48% over the same period.
Image source: Getty Images.
Source Fool.com
